Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 01, 2026
DataAggregated Company Financials
Companies147
  • 7D5.0%
  • 3M-5.4%
  • 1Y-3.2%
  • YTD-4.0%

The Healthcare industry is up 5.0% in the last week, with Swedish Orphan Biovitrum up 8.3%. During this same period, the Diamyd Medical underperformed, falling 90%. In the past year, the industry is down 3.2%. As for the next few years, earnings are expected to grow by 24% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Apr 2026SEK 560.4bSEK 229.0b-SEK 2,927,187,557.0230.4x-191.4x2.4x
Fri, 27 Feb 2026SEK 575.6bSEK 229.2b-SEK 1,620,513,611.8132.6x-355.2x2.5x
Sun, 25 Jan 2026SEK 598.2bSEK 257.5bSEK 5.6b40x106.7x2.3x
Tue, 23 Dec 2025SEK 584.8bSEK 230.6bSEK 3.7b43.3x160.2x2.5x
Thu, 20 Nov 2025SEK 583.9bSEK 230.5bSEK 2.9b44.8x200.7x2.5x
Sat, 18 Oct 2025SEK 601.1bSEK 227.1bSEK 6.7b42.6x90x2.6x
Mon, 15 Sep 2025SEK 613.4bSEK 227.0bSEK 6.6b45.5x93x2.7x
Wed, 13 Aug 2025SEK 609.2bSEK 226.8bSEK 6.6b46.9x92.2x2.7x
Fri, 11 Jul 2025SEK 642.1bSEK 226.7bSEK 6.0b44.9x106.7x2.8x
Sun, 08 Jun 2025SEK 630.5bSEK 226.5bSEK 5.8b43.8x107.9x2.8x
Tue, 06 May 2025SEK 599.2bSEK 223.6bSEK 4.9b36.9x122x2.7x
Thu, 03 Apr 2025SEK 567.4bSEK 220.7bSEK 5.4b35.6x105x2.6x
Sat, 01 Mar 2025SEK 584.8bSEK 206.2bSEK 4.3b35.8x136.4x2.8x
Mon, 27 Jan 2025SEK 583.0bSEK 202.6b-SEK 2,675,705,168.5040.6x-217.9x2.9x
Wed, 25 Dec 2024SEK 577.8bSEK 202.7b-SEK 2,503,854,548.6138.4x-230.7x2.8x
Fri, 22 Nov 2024SEK 499.6bSEK 200.0b-SEK 2,721,737,001.2737x-183.6x2.5x
Sun, 20 Oct 2024SEK 599.2bSEK 198.9b-SEK 3,204,651,387.2939.4x-187x3x
Tue, 17 Sep 2024SEK 621.9bSEK 200.0b-SEK 2,795,395,233.1741.7x-222.5x3.1x
Thu, 15 Aug 2024SEK 581.7bSEK 199.9b-SEK 2,561,710,497.7941.5x-227.1x2.9x
Sat, 13 Jul 2024SEK 585.4bSEK 196.1b-SEK 3,117,178,694.3238.3x-187.8x3x
Mon, 10 Jun 2024SEK 564.1bSEK 195.9b-SEK 3,147,692,207.7736.4x-179.2x2.9x
Wed, 08 May 2024SEK 543.6bSEK 196.6b-SEK 3,070,655,585.5035.6x-177x2.8x
Fri, 05 Apr 2024SEK 525.1bSEK 192.9b-SEK 3,320,820,680.8445.9x-158.1x2.7x
Sun, 03 Mar 2024SEK 512.0bSEK 192.0b-SEK 3,663,022,021.3645.1x-139.8x2.7x
Tue, 30 Jan 2024SEK 554.0bSEK 191.6b-SEK 892,587,250.0049.3x-620.7x2.9x
Thu, 28 Dec 2023SEK 539.0bSEK 191.0b-SEK 960,479,695.0047.5x-561.1x2.8x
Sat, 25 Nov 2023SEK 501.3bSEK 190.0b-SEK 1,225,557,640.0050.2x-409x2.6x
Mon, 23 Oct 2023SEK 422.0bSEK 185.5b-SEK 1,926,276,118.0031.5x-219.1x2.3x
Wed, 20 Sep 2023SEK 442.5bSEK 185.7b-SEK 1,987,704,802.0035.1x-222.6x2.4x
Fri, 18 Aug 2023SEK 460.1bSEK 184.3b-SEK 1,028,536,507.0040.2x-447.4x2.5x
Sun, 16 Jul 2023SEK 465.5bSEK 179.6b-SEK 866,115,788.0044.4x-537.5x2.6x
Tue, 13 Jun 2023SEK 522.4bSEK 179.0b-SEK 766,462,280.0042.8x-681.5x2.9x
Thu, 11 May 2023SEK 510.6bSEK 176.8b-SEK 906,363,284.0042x-563.3x2.9x
Sat, 08 Apr 2023SEK 504.0bSEK 172.7b-SEK 1,416,606,834.0035.7x-355.7x2.9x
Price to Earnings Ratio

-355.7x


Total Market Cap: SEK 504.0bTotal Earnings: -SEK 1,416,606,834.00Total Revenue: SEK 172.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -164.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.48%
Healthcare4.98%
Pharma5.94%
Biotech5.92%
Healthcare Services5.38%
Medical Equipment4.01%
Healthtech3.21%
Life Sciences2.88%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 392.208.3%
+SEK 10.4b		37.3%PE283.6x
ASKER Asker Healthcare GroupSEK 69.2010.1%
+SEK 2.4b		-15.5%PE57.5x
CAMX CamurusSEK 467.006.8%
+SEK 1.8b		-19.8%PE37.9x
IMP A SDB ImplanticaSEK 44.9515.9%
+SEK 1.7b		57.7%PS561.4x
SECT B SectraSEK 226.203.3%
+SEK 1.4b		-9.4%PE81.1x

Latest News

BICO
SEK 16.69
BICO Group
7D
-1.8%
1Y
-46.3%
DMYD B
SEK 1.53
Diamyd Medical
7D
-90.1%
1Y
-81.4%
SOBI
SEK 392.20
Swedish Orphan Biovitrum
7D
8.3%
1Y
37.3%
EKTA B
SEK 55.20
Elekta
7D
-2.7%
1Y
3.0%
GETI B
SEK 188.55
Getinge
7D
2.6%
1Y
-15.3%

Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Mar 29
Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
MAGLE
SEK 4.08
Magle Chemoswed Holding
7D
-45.6%
1Y
-86.1%
ONCO
SEK 1.42
Oncopeptides
7D
-6.0%
1Y
-14.9%

ONCO: Rights Offering And 2025 Sales Guidance Will Support Bullish View

Analysts have kept their SEK price target for Oncopeptides effectively unchanged, pointing to stable fair value assumptions and only marginal tweaks to inputs such as the discount rate, forecast revenue growth, profit margin and future P/E multiple. What's in the News Oncopeptides has filed a follow on equity offering of Ordinary Shares, targeting SEK 200.4 million through a rights offering of 129,283,736 shares at SEK 1.55 per share (Key Developments).
ASKER
SEK 69.20
Asker Healthcare Group
7D
10.1%
1Y
-15.5%
FLUO
SEK 36.00
FluoGuide
7D
-5.5%
1Y
-2.2%
CURAS
DKK 13.95
Curasight
7D
-6.4%
1Y
81.2%
BONEX
SEK 194.90
Bonesupport Holding
7D
8.9%
1Y
-37.9%

BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential

Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
VIMIAN
SEK 28.00
Vimian Group
7D
9.8%
1Y
-37.1%
SECT B
SEK 226.20
Sectra
7D
3.3%
1Y
-9.4%

SECT B: Cloud Deals And Rating Upgrades Will Shape Balanced Return Profile

Sectra's analyst price target has been revised from SEK 220 to about SEK 228. Analysts have issued refreshed Buy ratings and higher targets in the SEK 210 to SEK 250 range that reflect updated views on growth, profitability and future P/E assumptions.
CAMX
SEK 467.00
Camurus
7D
6.8%
1Y
-19.8%

CAMX: 2026 Guidance And US FDA Review Will Drive Future Upside

Analysts have kept their SEK 930 price target for Camurus unchanged, citing only minor adjustments in their assumptions for revenue growth, profit margin and future P/E as the main reasons for maintaining this level. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).
ORT B
SEK 7.66
Ortoma
7D
-10.9%
1Y
-17.8%
IMP A SDB
SEK 44.95
Implantica
7D
15.9%
1Y
57.7%